Trials / Completed
CompletedNCT00922987
Clinical Study With Lyrica In Patients Suffering From Epilepsy
Non-Interventional Study (NIS) With Lyrica In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 286 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Clinical study with Lyrica (pregabalin) in patients suffering from epilepsy. This drug is used as adjunctive therapy with one or more antiepileptics. Lyrica has potential to reduce seizure frequency.
Detailed description
\- Included all adult patients with partial seizures and without contraindications according to Summary of Product Characteristics (SmPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lyrica (pregabalin) | The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg) |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2009-06-18
- Last updated
- 2021-01-25
- Results posted
- 2011-06-21
Locations
61 sites across 1 country: Slovakia
Source: ClinicalTrials.gov record NCT00922987. Inclusion in this directory is not an endorsement.